Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01369953 |
Recruitment Status
:
Completed
First Posted
: June 9, 2011
Last Update Posted
: April 5, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Since 2007, the cost of sequencing a diploid human genome has fallen dramatically, from approximately $70 million to $20,000. As affordable sequencing platforms become more widely available, the advancement of biomedical science will draw increasingly on whole genome sequencing research requiring large cohorts of diverse populations. Key policy, ethical and legal implications of these developments will need to be understood in order to promote the efficacy and effectiveness of genomic research going forward.
An overall aim of this project is to obtain feedback on the informed consent process from some of the earliest particpants in studies using whole genome sequencing. A more specific goal is to characterize the salient personal and public references accessed by participants around the time of the informed consent process. By highlighting trends in participants views about study participation around the time of the initial informed consent process, we aim to advance the development of an ethically and socially relevant vocabulary with which to negotiate future terms of use for personal sequence data in genomic research.
Participants will be asked to complete a one-time, semi-structured telephone interview lasting approximately 45 minutes in the period 2-8 weeks following their initial informed consent session at the NIH. They will be recruited from two NIH protocols employing whole genome sequencing for distinct purposes. They The ClinSeqTM Study is a large-scale medical sequencing project investigating the causal role of genetics in cardiovascular disease enrolling both symptomatic and healthy individuals. The Whole Genome Medical Sequencing for Gene Discovery Study (WGMS) enrolls children and adults for full sequencing with the aim of discovering the genetic etiology of rare conditions.
Condition or disease |
---|
Coronary Artery Disease Proteus Syndrome Coffin - Sins Syndrome Familial Isolated Hyperparathyroidism Dubouitz Syndrome |
Since 2007, the cost of sequencing a diploid human genome has fallen dramatically, from approximately $70 million to $20,000 (Illumina, 2010). As affordable sequencing platforms become more widely available, the advancement of biomedical science will draw increasingly on whole genome sequencing research requiring large cohorts of diverse populations (Lunshof et al., 2009; Need & Goldstein, 2009). Key policy, ethical and legal implications of these developments will need to be understood in order to promote the efficacy and effectiveness of genomic research going forward.
<TAB>
In addition to information about well-understood regions of the genome both sought-after and incidental whole genome sequencing yields results of probabilistic, uncertain, and changing significance over indefinite periods of time. Sequence data is most useful when shared widely among investigators in conjunction with detailed clinical information (Angrist, 2010). It may have implications for individuals and families and be of unclear clinical significance. As such, the boundary between clinical and research testing is dissolving, and standards for returning test results to research participants are non-existent (McGuire & Lupski, 2010). The difficulty of acquiring informed consent for studies involving whole genome sequencing is therefore a topic of active debate within the biomedical research community.
This proposed study approaches both informed consent and genomic medicine as iterative constructs shaped by civic values and social norms. Understanding the civic and social contexts where informed consent takes place is crucial in order to adapt it to new realities in genomic research. An overall aim of this inquiry is to solicit feedback on the informed consent process from some of the earliest adopters of whole genome sequencing in research. A more specific goal is to characterize the salient personal and public references accessed by participants around the time of the informed consent process. By highlighting trends in and relationships between these civic values and social norms, we aim to advance the development of an ethically and socially relevant vocabulary with which to broker terms of use for personal sequence data.
Participants will be recruited from two NIH protocols employing whole genome sequencing for distinct purposes. The ClinSeqTM Study is a large-scale medical sequencing project investigating the causal role of genetics in cardiovascular disease enrolling both symptomatic and healthy individuals. The Whole Genome Medical Sequencing for Gene Discovery Study (WGMS) enrolls children and adults for full sequencing with the aim of discovering the genetic etiology of rare conditions.
Study Type : | Observational |
Actual Enrollment : | 30 participants |
Time Perspective: | Prospective |
Official Title: | Informed Consent for Whole Genome Sequencing: Civic Ideals and Social Norms Referenced by Early Participants |
Study Start Date : | May 29, 2011 |
Study Completion Date : | January 31, 2014 |

- Qualitative Description

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
- INCLUSION CRITERIA:
- Adult over 18 years of age
- English-speaking
- Individuals consented to participate in either the NIH's ClinSeq or Whole Genome Medical Sequencing for Gene Discovery protocols
EXCLUSION CRITERIA:
- Children under 18 years of age
- Non-English speakers
- Individuals consented to participate in either the NIH's ClinSeq or Whole Genome Medical Sequencing for Gene Discovery protocols more than 8 weeks prior to their recruitment for this study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01369953
United States, Maryland | |
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike | |
Bethesda, Maryland, United States, 20892 |
Principal Investigator: | Barbara B Biesecker | National Human Genome Research Institute (NHGRI) |
Publications:
ClinicalTrials.gov Identifier: | NCT01369953 History of Changes |
Other Study ID Numbers: |
999911185 11-HG-N185 |
First Posted: | June 9, 2011 Key Record Dates |
Last Update Posted: | April 5, 2018 |
Last Verified: | January 31, 2014 |
Keywords provided by National Institutes of Health Clinical Center (CC):
Civic Ideals/Social Norms Genetic Counseling Genetic Disorders Genetic Testing Whole Genome Sequencing |
Additional relevant MeSH terms:
Syndrome Coronary Artery Disease Myocardial Ischemia Coronary Disease Hyperparathyroidism Proteus Syndrome Hyperparathyroidism, Primary Disease Pathologic Processes Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases |
Parathyroid Diseases Endocrine System Diseases Hamartoma Syndrome, Multiple Hamartoma Neoplasms Neoplasms, Multiple Primary Bone Diseases, Developmental Bone Diseases Musculoskeletal Diseases Limb Deformities, Congenital Musculoskeletal Abnormalities Abnormalities, Multiple Congenital Abnormalities |